CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
In July, all 5 CTS laboratories will convert from the current Grifols Ultrio Plus NAT triplex assay ...
National Blood Donor Month has been observed in January since 1970, with the goal of increasing bloo...
Reminder: On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the ch...
The new Learning Center website launch today on Monday, March 30, 2020. While the link to the new Le...